US equities |
SPCX $166.69 ▲+4.86% NVDA $236.84 ▲+1.23% MU $1,063.76 ▼-1.04% TSLA $377.53 ▲+1.87% MSFT $526.35 ▲+1.70% SNDK $1,713.00 ▼-0.41% INTC $117.18 ▼-1.80% META $745.10 ▲+2.34%
FinancialContent

Cyclacel Pharmaceuticals, Inc. - 6% Convertible Preferred Stock (NQ:CYCCP)

5.050 UNCHANGED
Last Price Updated: 3:01 PM EDT, Sep 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cyclacel Pharmaceuticals, Inc. - 6% Convertible Preferred Stock

< Previous 1 2 3 Next >
News headline image
Bio Green Med Solution, Inc. Announces Closing of Strategic Acquisition of Fitters Sdn. Bhd.
From Bio Green Med Solution, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update
From Cyclacel
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Cyclacel Pharmaceuticals Announces Stock Split
From Cyclacel
Via GlobeNewswire
News headline image
Cyclacel Pharmaceuticals Announces $3 Million Private Placement Offering of Convertible Preferred Stock
From Cyclacel
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update
From Cyclacel
Via GlobeNewswire
News headline image
Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred Stock
From Cyclacel
Via GlobeNewswire
News headline image
Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership
From Cyclacel
Via GlobeNewswire
News headline image
Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar
David Lazar agrees to invest $3.1 million in Preferred Stock and becomes Interim CEO 
From Cyclacel
Via GlobeNewswire
News headline image
Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs
From Cyclacel
Via GlobeNewswire
News headline image
Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds
From Cyclacel
Via GlobeNewswire
News headline image
Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds
From Cyclacel
Via GlobeNewswire
News headline image
Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update
From Cyclacel
Via GlobeNewswire
News headline image
Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule
From Cyclacel
Via GlobeNewswire
News headline image
Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
- Interim data for fadraciclib monotherapy in patients with advanced solid tumors preselected for CDKN2A and/or CDKN2B abnormalities - 
From Cyclacel
Via GlobeNewswire
News headline image
Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
Initial safety and efficacy data from fadraciclib monotherapy in patients with advanced solid tumors preselected for CDKN2A and/or CDKN2B abnormalities 
From Cyclacel
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study
From Cyclacel
Via GlobeNewswire
News headline image
Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference
From Cyclacel
Via GlobeNewswire
News headline image
Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter
Delisting or suspension action stayed pending the issuance of a final decision 
From Cyclacel
Via GlobeNewswire
News headline image
Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update
From Cyclacel
Via GlobeNewswire
News headline image
Cyclacel Pharmaceuticals to Release Second Quarter 2024 Financial Results
From Cyclacel
Via GlobeNewswire
News headline image
Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions
Lengthens Patent Exclusivity of Plogosertib until August 2040 
From Cyclacel
Via GlobeNewswire
News headline image
Cyclacel’s Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting
From Cyclacel
Via GlobeNewswire
News headline image
Cyclacel Pharmaceuticals Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib’s Potential as a Precision Medicine for Cancer
From Cyclacel
Via GlobeNewswire
News headline image
Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update
From Cyclacel
Via GlobeNewswire
News headline image
Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results
From Cyclacel
Via GlobeNewswire
< Previous 1 2 3 Next >